Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth.
GNAQ
fatty acid synthase
mTOR pathway
metabolic inhibition
uveal melanoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Jun 2023
30 Jun 2023
Historique:
received:
07
06
2023
revised:
25
06
2023
accepted:
27
06
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Uveal melanoma (UM) displays a high frequency of metastasis; however, effective therapies for metastatic UM are limited. Identifying unique metabolic features of UM may provide a potential targeting strategy. A lipid metabolism protein expression signature was induced in a normal choroidal melanocyte (NCM) line transduced with
Identifiants
pubmed: 37444561
pii: cancers15133451
doi: 10.3390/cancers15133451
pmc: PMC10341317
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NIH HHS
ID : R01 CA196278
Pays : United States
Organisme : NIH HHS
ID : R01 CA253977
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA196278
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA010815
Pays : United States
Organisme : NIH HHS
ID : P01 CA114046
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA253977
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM138943
Pays : United States
Organisme : NIH HHS
ID : R01 CA257505
Pays : United States
Organisme : NCI NIH HHS
ID : DP2 CA249950
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA221675
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA114046
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM144302
Pays : United States
Organisme : NIH HHS
ID : NIH R50CA221675
Pays : United States
Organisme : Melanoma Research Alliance
ID : 559058
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA257505
Pays : United States
Organisme : NCI NIH HHS
ID : NCI CA16672
Pays : United States
Références
Oncotarget. 2016 Apr 26;7(17):23633-46
pubmed: 26988753
Br J Cancer. 2020 Jan;122(2):136-149
pubmed: 31819196
Sci Rep. 2019 Jun 24;9(1):9142
pubmed: 31235702
Acta Biomater. 2019 Jan 15;84:305-316
pubmed: 30476582
Oncotarget. 2016 Aug 2;7(31):49623-49635
pubmed: 27391064
Cell. 2019 Jun 13;177(7):1933-1947.e25
pubmed: 31160049
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Sci Adv. 2016 May 27;2(5):e1600200
pubmed: 27386546
J Clin Oncol. 1999 May;17(5):1474-81
pubmed: 10334533
Mol Vis. 2017 Oct 03;23:680-694
pubmed: 29033534
Anal Chem. 2010 Dec 1;82(23):9818-26
pubmed: 21049934
Cancer Chemother Pharmacol. 2019 Jul;84(1):15-32
pubmed: 31079217
Oncogene. 2022 Feb;41(8):1129-1139
pubmed: 35046531
Sci Adv. 2019 Sep 18;5(9):eaax1738
pubmed: 31555735
Cell Chem Biol. 2016 Jun 23;23(6):678-88
pubmed: 27265747
Mol Cancer Ther. 2015 Nov;14(11):2508-18
pubmed: 26358751
Oncogene. 2016 Feb 4;35(5):642-50
pubmed: 25893295
Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4187-4195
pubmed: 31596927
FEBS J. 2018 Feb;285(3):432-443
pubmed: 28971574
J Oncol. 2018 Dec 02;2018:1908065
pubmed: 30631354
Pigment Cell Melanoma Res. 2022 Jan;35(1):78-87
pubmed: 34347929
Expert Opin Ther Targets. 2017 Nov;21(11):1001-1016
pubmed: 28922023
Ophthalmol Clin North Am. 2005 Mar;18(1):75-84, viii
pubmed: 15763193
Nat Commun. 2020 Apr 20;11(1):1894
pubmed: 32313009
PLoS One. 2012;7(7):e40439
pubmed: 22808163
Cells. 2020 Nov 10;9(11):
pubmed: 33182594
Cancers (Basel). 2022 Jul 28;14(15):
pubmed: 35954340
Oncogene. 2014 Sep 25;33(39):4724-34
pubmed: 24141786
Curr Opin Oncol. 2018 Mar;30(2):134-141
pubmed: 29206651
Nat Rev Drug Discov. 2022 Feb;21(2):141-162
pubmed: 34862480
J Pathol. 2019 Apr;247(5):539-551
pubmed: 30511391
Cell Metab. 2013 Aug 6;18(2):153-61
pubmed: 23791484
Cancer Res. 1953 Jan;13(1):27-9
pubmed: 13032945
Aging (Albany NY). 2020 May 12;12(10):9745-9760
pubmed: 32401230
Trends Cancer. 2021 Aug;7(8):671-681
pubmed: 34127435
Nature. 2009 Jan 29;457(7229):599-602
pubmed: 19078957
Oncotarget. 2018 May 15;9(37):24787-24800
pubmed: 29872506
Pharmacol Ther. 2022 Nov;239:108200
pubmed: 35513054
Cancers (Basel). 2020 Jun 10;12(6):
pubmed: 32532044
Nat Commun. 2020 Jan 24;11(1):496
pubmed: 31980621
Mol Oncol. 2014 Dec;8(8):1508-20
pubmed: 24994677
Nat Commun. 2019 Nov 1;10(1):5011
pubmed: 31676791
FEBS J. 2016 Aug;283(15):2767-78
pubmed: 26881388
Cancer Res. 2021 Jun 1;81(11):2807-2814
pubmed: 33446574
J Clin Oncol. 2018 Apr 20;36(12):1232-1239
pubmed: 29528792
Br J Cancer. 2020 Jan;122(1):4-22
pubmed: 31819192
Pharmacol Res. 2016 Sep;111:523-533
pubmed: 27436149
Cancer Imaging. 2014 Nov 12;14:30
pubmed: 25609545
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Oncogene. 2016 Mar 10;35(10):1250-60
pubmed: 26028026
Curr Opin Lipidol. 2012 Jun;23(3):226-234
pubmed: 22449814
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
N Engl J Med. 2021 Sep 23;385(13):1196-1206
pubmed: 34551229
Nat Rev Nephrol. 2017 Mar;13(3):143-151
pubmed: 28090081
Nat Rev Drug Discov. 2011 Aug 31;10(9):671-84
pubmed: 21878982
Cancer Biol Med. 2014 Mar;11(1):1-19
pubmed: 24738035
DNA Cell Biol. 2018 Feb;37(2):99-108
pubmed: 29240458
Invest Ophthalmol Vis Sci. 1993 Jun;34(7):2210-9
pubmed: 8505203
Clin Ophthalmol. 2017 Jan 31;11:279-289
pubmed: 28203054
Oncogene. 2021 Jan;40(3):618-632
pubmed: 33208912
Curr Pharm Des. 2014;20(15):2619-26
pubmed: 23859617
Clin Cancer Res. 2015 Dec 15;21(24):5434-8
pubmed: 26519059
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Oncotarget. 2015 Aug 7;6(22):18891-904
pubmed: 25970773
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2037-42
pubmed: 20133848
Oncogenesis. 2017 Jun 12;6(6):e347
pubmed: 28604762
Mol Cancer Ther. 2006 Oct;5(10):2512-21
pubmed: 17041095
PLoS One. 2011 Jan 28;6(1):e16516
pubmed: 21305041
J Immunother Cancer. 2019 Nov 13;7(1):299
pubmed: 31722735
PLoS One. 2016 Jan 25;11(1):e0147717
pubmed: 26808816
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Proc Natl Acad Sci U S A. 2022 May 10;119(19):e2107006119
pubmed: 35512098
Br J Cancer. 1979 Jun;39(6):681-7
pubmed: 444407
Nat Commun. 2020 May 15;11(1):2408
pubmed: 32415113
Mol Cancer Ther. 2017 Mar;16(3):516-528
pubmed: 28138035